Congrats to Dr. Gregory Lee on administering the first and only FDA-approved treatment designed to block VEGF and Ang-2† vision loss, VABYSMOⓇ (faricimab-svoa), at Georgia Retina! By embracing the latest technology available, our affiliates empower their patients to achieve the best surgical outcomes possible! #ophthalmology #ophthalmologist #eyecare #surgicaladvances #vabysmo #newtech
Exciting news from Georgia Retina! 📣 This morning, our esteemed Dr. Greg Lee administered the new VABYSMO PFS (Prefilled Syringe), marking another milestone in our commitment to cutting-edge eye care, this time in a safer more efficient delivery device. VABYSMO is the only treatment targeting two pathways that lead to vision loss for nAMD, DME and RVO. It acts as both a vascular endothelial growth factor (VEGF) inhibitor and an angiopoietin-2 (Ang-2) inhibitor. It's indicated for the treatment of: •Neovascular (Wet) Age-Related Macular Degeneration •Diabetic Macular Edema •Macular Edema following Retinal Vein Occlusion At Georgia Retina, we are dedicated to providing excellence in care and staying at the forefront of ophthalmic advancements. By adopting the most efficient medications and technologies, we ensure our patients receive the best possible treatment outcomes. We are proud to offer VABYSMO PFS as part of our comprehensive eye care services. If you have questions about this treatment or would like to schedule a consultation, please do not hesitate to reach out. #EyeCare #Ophthalmology #MedicalInnovation #GeorgiaRetina #VABYSMOPFS #Genentech Gregory Lee EyeSouth Partners